JMP Securities raised the firm’s price target on Hookipa Pharma to $24 from $23 and keeps an Outperform rating on the shares. Hookipa Pharma reported Q2 results, ending the quarter with $77M in cash, which the firm believes will be sufficient into the second half of 2025, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Hookipa Pharma Announces Executive Reshuffle and Board Enhancements
- Hookipa Pharma price target lowered to $23 from $50 at JMP Securities
- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
- Hookipa Pharma appoints Peters as CEO, Coelho as EVP, CFO
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue